Molecular Insight Hits USPTO Over Patent Terms

Law360, New York (December 3, 2008, 12:00 AM EST) -- Molecular Insight Pharmaceuticals Inc. has filed two suits against the U.S. Patent and Trademark Office over its refusal to extend the term patents owned or licensed by the drug company in the latest of a string of patent term adjustment actions following a recent district court decision against the agency.

The complaints, both filed in the U.S. District Court for the District of Columbia, name USPTO and Under Secretary for Commerce for Intellectual Property Jon W. Dudas in its allegations that the office improperly applied the...
To view the full article, register now.